



NEWS RELEASE

## **PALADIN LABS ANNOUNCES CANADIAN LAUNCH OF TWINJECT FOR ANAPHYLAXIS**

**First Advancement in Self-Administered Treatment Options Since 1980s**

**First and Only Dual-Dose Product for Anaphylaxis**

**Montreal, Canada, September 22, 2005** – Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, today announced the Canadian launch of Twinject™, a novel epinephrine auto-injector indicated for the emergency treatment of severe allergic reactions (anaphylaxis). Twinject is the first and only product approved by Health Canada that contains two doses of epinephrine in a single device. Twinject is available in two dosages (0.3 mg and 0.15 mg) for self-administration.

“There are times when one dose of epinephrine may not suffice. More than a third of patients with severe allergic reactions may need a back-up dose to manage their anaphylactic reaction. These patients need to carry a minimum of two doses of epinephrine with them at all times,” said Dr. Peter Vadas, Director of Allergy and Clinical Immunology at St. Michael’s Hospital in Toronto.

“The dual-dose capability of Twinject addresses an unmet medical need and may save lives. Published studies have demonstrated that more than one dose of epinephrine may be required in up to 36 percent of the anaphylactic episodes to properly address the reaction, with the second dose often needed within 5-10 minutes after the first dose. As such, we are very excited to be bringing this novel product line to Canadian patients at risk for anaphylaxis,” said Jonathan Ross Goodman, President & CEO of Paladin Labs.

### **About Anaphylaxis**

Anaphylaxis is a severe, life-threatening systemic allergic reaction triggered by exposure to one or more various antigens, including foods, insect stings, drugs, and latex products. Up to eight percent of children have food allergies, with allergies to peanuts and tree nuts among children having doubled in the past five years. The timing, location, pattern (including onset, severity and length) and specific treatment requirements for each future anaphylactic episode cannot be predicted in advance. According to IMS Canada, in 2004 the anaphylaxis market was \$25 million and has grown 22 percent per year since 2001. It is estimated by the Canadian Anaphylaxis Society that there are over 600,000 Canadians at risk for anaphylaxis.

**About Twinject**

Twinject is a pre-filled, pen size auto-injector with two doses of epinephrine for the emergency treatment of severe allergic reactions (anaphylaxis). The first dose is administered using the auto-injector. The second dose, if needed, is administered via a pre-filled syringe located inside the barrel of the device. Twinject is available in a compact, crush-resistant carrying case, with instructions for use attached to the device; it also has a small gauge needle. In addition, there will be a consumer campaign called **Twinject Be Ready**, which aims to provide comprehensive patient training and support. For more information about Twinject, please visit [www.twinject.ca](http://www.twinject.ca).

**About Paladin Labs Inc.**

Paladin Labs, headquartered in Montreal, Canada, is a leading specialty pharmaceutical company focused on developing, acquiring or in-licensing innovative pharmaceutical products for the Canadian market. With this strategy, a focused national sales team and proven marketing expertise, Paladin has evolved into one of Canada's leading specialty pharmaceutical companies. Paladin's shares trade on the Toronto Stock Exchange under the symbol *PLB*. For more information about Paladin, please visit the Paladin Web Site at [www.paladinlabs.com](http://www.paladinlabs.com).

*This news release may contain forward-looking statements or predictions. These statements represent our judgement as of this date and are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed in such forward-looking statements. Potential risks and uncertainties include, without limitation, those associated with product development, clinical trials, future revenues and profitability, and obtaining marketing approval and other factors that are discussed in the Management Discussion and Analysis published in the Company's annual report.*

**For more information, please contact:**

Samira Sakhia  
Chief Financial Officer

**Paladin Labs Inc.**

Tel: (514) 340-5067

Email: [info@paladin-labs.com](mailto:info@paladin-labs.com)

Website: [www.paladinlabs.com](http://www.paladinlabs.com)